Myriad Genetics (MYGN) has disclosed a new risk, in the Taxation & Government Incentives category.
Myriad Genetics faces significant business risk from potential changes in tax laws or their interpretations, which could adversely impact its financial condition. Operating in multiple U.S. and foreign tax jurisdictions, the company is vulnerable to legislative shifts or reinterpretations by entities like the IRS and the U.S. Treasury Department. Such changes, especially those with retroactive effects, could increase tax liabilities or require operational adjustments, posing a challenge as the timing and specifics of new tax laws remain unpredictable. The uncertainty surrounding future tax regulations adds a layer of complexity to Myriad Genetics’ financial planning and risk management strategies.
The average MYGN stock price target is $15.22, implying 41.85% upside potential.
To learn more about Myriad Genetics’ risk factors, click here.